Compare Crispr Therapeutics AG (CRSP) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Payoneer Global Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: Crispr Therapeutics AG is far larger — about 2.2× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PAYO | |
|---|---|---|
Market Cap | $5.23B | $2.40B |
Sector | Health | Technology |
52-Week High | $76.78 | $7.17 |
52-Week Low | $44.34 | $4.27 |
Enterprise Value | $3.65B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Payoneer Global Inc. (PAYO) trades at $7.09, down 0.14% on the day, near its 52-week high of $7.67. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal mixed earnings with Q2 2026 EPS missing estimates at $0.02 versus $0.06 expected. Revenue growth remains solid, up 10% year-over-year excluding interest in Q2 2026. Sentiment is influenced by the pending acquisition by Nuvei for $7.40 per share, announced on June 15, 2026, which has sparked legal inquiries over fairness.
The outlook is cautiously optimistic with a consensus price target of $8.20 offering 16% upside, but risks include integration challenges from the Nuvei deal and earnings volatility. Investors should weigh the acquisition premium against potential shareholder litigation and execution risks in cross-border payment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
